Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer

Assiut University38 enrolled

Overview

Thyroid carcinoma is the most common endocrine malignancy. Surgery is the standard therapeutic approach for patients with differentiated thyroid carcinoma (DTC), followed by radioiodine (RAI) therapy if indicated. For women with DTC, the effects of RAI therapy on gonadal and reproductive function are an important consideration. This study aimed to evaluate the effects of RAI therapy on ovarian function.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Ovarian Insufficiency Radiation Exposure

Interventions

radioactive iodineRADIATION

80-200 mCi of radioactive iodine will be given to thyroid cancer patients

Eligibility

Sex: FEMALEMin age: 15 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female patient in childbearing period. * Female patient with differentiated thyroid carcinoma. * Underwent thyroidectomy. * Candidate for radioactive iodine therapy. Exclusion Criteria: * • Male patients. * Postmenopausal female patients. * Female patients with undifferentiated thyroid carcinoma. * Pregnant female patients. * Lactating female patients.

Outcomes

Primary Outcomes

Level of anti-Müllerian (AMH) hormone

Level of anti-Müllerian (AMH) hormone in female patients before and after radioactive iodine therapy.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.